A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
AT&T (T) is seeing a 6% surge in its stock price during midday trading following a strong set of Q4 results, reflecting ...
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
"attachment_1199023" align="aligncenter" width="1456"] An elderly couple receiving insulin from a pharmacist, representing ...
As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...
Here are some of the major companies whose stocks moved on the week’s news.
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback